摘要
The catastrophic pandemic of the coronavirus disease 2019(COVID-19)has caused serious harm to human life and global social economy.As of June 13,2022,there were more than 530 million confirmed cases of COVID-19 and over 6.3 million deaths[1].During the past 2 years,global studies on prevention and therapies for COVID-19 have achieved a series of promising findings,including antiviral drugs(Remdesivir,Molnupiravir,Paxlovid)and monoclonal antibodies(Bamlanivimab and Etesevimab,Sotrovimab,Casirivimab and Imdevimab)[2].
基金
This work was supported by the National Natural Science Foundation of China(A study on the correlation between TCM syndromes and disease outcome of COVID-19,No.82004505)
National Key Research and Development Program of China(Real-world study of traditional Chinese medicine for COVID-19,No.2021YFC0863200).
